Predicted from two receptor actions before the label is checked, the adverse effects of spironolactone in a composite retiree with heart failure are sorted into hits, misses and surprises for NU559. Searches like "nu 559 unit 7 assignment example", "nu559 unit 7 sample" and "nu559 unit 7 example" land here.
Predicting Spironolactone From Its Receptors, Then Opening the Label: An Adverse Effect Prediction for Heart Failure
[Student Name]
Purdue University Global
NU559: Essentials of Advanced Pathophysiology and Pharmacology
Unit 7 Adverse Effect Prediction
[Instructor Name]
[Date]
The patient is a composite; agents in brackets stand for their classes.
The Patient
Mr. [F.], 66, spent his career surveying land for county road projects. His left ventricle pumps weakly, with an ejection fraction of [30] percent, and his cardiologist plans to add [spironolactone] to [lisinopril], [carvedilol] and [furosemide]. His list also still carries [potassium chloride], started when he was on a higher furosemide dose. His potassium is [4.6] mmol/L and his eGFR [58].
Table 1: Predictions From Binding (written [date 1], before any reference)
On-target: mineralocorticoid receptor blockade.
1. Receptor: mineralocorticoid receptor in the collecting duct. Normal action: aldosterone increases sodium channels on the tubule's luminal side and the sodium-potassium pump on its blood side, reabsorbing sodium and secreting potassium and hydrogen ions. Predicted effect of blockade: potassium retention, high potassium. Confidence: high.
2. Same receptor. Predicted effect: less sodium and water reabsorbed, mild diuresis, lower blood pressure, possible dehydration and low sodium. Confidence: high.
3. Same receptor. Predicted effect: less hydrogen ion secretion, mild metabolic acidosis. Confidence: moderate.
4. Same receptor, with lower blood volume. Predicted effect: a small rise in creatinine as kidney perfusion falls. Confidence: moderate.
5. Mineralocorticoid receptor in the heart and vessels. Predicted effect: less fibrosis, the intended benefit. Confidence: high.
Off-target: spironolactone is a steroid, structurally similar to progesterone and testosterone, so it also binds sex hormone receptors.
6. Androgen receptor, blocked. Predicted effect: in men, breast enlargement and tenderness, reduced libido, erectile difficulty. Confidence: high.
7. Progesterone receptor, partly activated. Predicted effect: in women, menstrual irregularity and breast tenderness. Confidence: moderate.
Table 2: Predictions Against the Prescribing Information (checked [date 2])
1. High potassium: confirmed, with a boxed emphasis on monitoring.
2. Diuresis, low blood pressure, dehydration, low sodium: confirmed.
3. Metabolic acidosis: confirmed, as hyperchloremic metabolic acidosis, particularly in decompensated liver disease.
4. Creatinine rise: confirmed, as impaired kidney function.
5. Reduced fibrosis: not listed as an adverse effect, as expected; it is the benefit.
6. Breast enlargement and sexual effects in men: confirmed.
7. Menstrual changes in women: confirmed.
Listed but unpredicted by any receptor argument: gastrointestinal effects, including nausea, cramping and diarrhea; drowsiness, lethargy and headache; rash; and rare serious reactions, including agranulocytosis and severe skin reactions.
What the Pattern Shows
Every on-target and off-target prediction was confirmed. Receptor pharmacology predicted the common, dose-related effects well; it did not predict the rare, idiosyncratic ones, which arise from immune or individual reactions rather than from the drug's intended binding.
The on-target predictions follow from the collecting duct. By blocking aldosterone, spironolactone reduces sodium entry through the epithelial sodium channel, so the electrical gradient that drives potassium into the urine weakens and potassium stays in the blood. In the trial that established its benefit in severe heart failure, spironolactone reduced deaths by about 30 percent, while serious high potassium was uncommon under close monitoring (Pitt et al., 1999).
The off-target predictions follow from structure. In the same trial, breast enlargement or pain occurred in about one in ten men on spironolactone compared with one in a hundred on placebo (Pitt et al., 1999). Eplerenone, a more selective mineralocorticoid receptor antagonist, binds sex hormone receptors far less, and in its heart failure trial, those effects were rare (Zannad et al., 2011). That contrast confirms the receptor explanation: remove the off-target binding and the off-target effects largely go.
Amplifiers on His List
The highest-confidence prediction, high potassium, is the one most amplified by his other medicines.
1. [Potassium chloride]: adds potassium directly. It should be reviewed and probably stopped before spironolactone starts.
2. [Lisinopril]: reduces angiotensin II formation, lowering aldosterone secretion and potassium excretion.
3. Reduced kidney function: an eGFR of 58 means less capacity to excrete potassium.
4. A future amplifier: [trimethoprim], if an antibiotic is ever added, blocks the collecting duct's sodium channels and further raises potassium.
The prediction is not only theoretical. After the 1999 trial was published, spironolactone prescribing for heart failure rose sharply in Ontario, and admissions and deaths from high potassium rose with it, among older adults also taking ACE inhibitors (Juurlink et al., 2004).
Monitoring That Follows From the Prediction
Potassium and creatinine checked before starting, at about three days and one week, then monthly for three months and periodically after. Stop potassium chloride unless levels are low. Hold spironolactone if potassium rises above [5.5] mmol/L. Ask about breast tenderness at each visit, and offer eplerenone if it develops.
References
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004). Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine, 351(6), 543-551. https://doi.org/10.1056/NEJMoa040135
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341(10), 709-717. https://doi.org/10.1056/NEJM199909023411001
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine, 364(1), 11-21. https://doi.org/10.1056/NEJMoa1009492
How this NU559 Unit 7 example is structured
Its design keeps the order of work visible: prediction, then verification, then explanation. Dating the two tables separately is the device that shows the prediction came first. Predictions are grouped by receptor rather than by organ, because the unit's point is that adverse effects descend from binding. The on-target group, from aldosterone blockade at the collecting duct, explains potassium retention through reduced sodium channel activity and reduced potassium secretion. The off-target group explains why a structurally steroidal drug reaches sex hormone receptors, and why eplerenone, more selective, rarely produces those effects. RALES (1999) is cited for benefit, and a 2004 population study by Juurlink and colleagues for the rise in hyperkalemia admissions that followed wider prescribing, which turns a prediction into a documented pattern. Misses are discussed openly, including effects no receptor argument predicted.
Get an NU559 Unit 7 example written to your instructions
Prediction exercises vary by drug, so name the agent the NU559 Unit 7 prompt hands you and paste any case details alongside the rubric. The returned sample predicts from receptor binding before any reference is opened, dates both tables and keeps every value in brackets. It arrives in 24-48h, and your first sample is free. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU559 Unit 7 questions, answered
How can a grader tell the predictions came before the reference?
Often from the pattern itself. Genuine predictions include uncertain ones and a few that turn out wrong; backward predictions are uniformly correct and oddly specific. Dating the tables and stating confidence helps, and some sections ask for the prediction table as a separate submission. Honest misses tend to earn more than a suspiciously perfect record.
Should predictions include frequency or only the type of effect?
Type and direction are usually enough, with a qualitative likelihood such as expected, possible or unlikely. Exact percentages cannot come from mechanism alone, and inventing them undermines the exercise. Frequencies belong in the verification table, taken from the prescribing information or a pharmacology reference and cited with the specific source used.
What if the assigned drug has a poorly understood mechanism?
Say so and predict from what is known, stating that confidence is lower. A drug whose target is uncertain still has a class, a structure and known effects on organ systems, and those support cautious predictions. The paper can then treat the gap between prediction and label as evidence about how much of the mechanism is actually settled.